Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Clearmind Medicine Inc. is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to address underserved health issues. Its primary efforts center on treatments for alcohol use disorder, including the lead candidate CMND-100, which is in an FDA-approved Phase I/IIa clinical trial, and MEAI, a non-hallucinogenic neuroplastogen targeted at obesity, metabolic disorders, compulsive eating, binge drinking, eating disorders, anxiety, depression, and post-traumatic stress disorder. The company also explores intranasal formulations and collaborations to enhance drug delivery for addiction-related and central nervous system conditions. Clearmind Medicine Inc. maintains an extensive intellectual property portfolio comprising 15 patent families with granted and pending patents across multiple jurisdictions. Founded in 2017 and headquartered in Vancouver, Canada, it operates as a key player in the emerging field of psychedelic medicines for mental health and behavioral disorders.
$2.49
$0.19 (-7.09%)
EOD Jun 25, 2026 · Twelve Data
Negative free cash flow of -$5M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$8M
▲ +26.6% YoY
Op. Margin
—
ROIC
-146.02%
▲ +90.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$6M
▲ +2.6% YoY
Op. Cash Flow (TTM)
-$5M
▲ +31.3% YoY
Net Debt
-$4M
Net Cash Position
Cash & Equiv.
$6M
Continue Research
Clearmind Medicine (CMND)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Clearmind Medicine scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Clearmind Medicine scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -146.0% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh CMND's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.